AMENDMENT NUMBER THIRTEEN TO EXPRESS SCRIPTS, INC. PHARMACY BENEFIT MANAGEMENT AGREEMENT

This AMENDMENT NUMBER THIRTEEN (the "Amendment") is entered into as of the Effective Date, by and between EXPRESS SCRIPTS, INC., a Delaware corporation ("ESI"), and COUNTY OF VENTURA as owner of the VENTURA COUNTY HEALTH CARE PLAN, a health care service plan organized under the laws of the State of California ("Sponsor").

RECITALS

- A. ESI and Sponsor are parties to a Pharmacy Benefit Management Agreement dated as of October 18, 2011, as amended from time to time (the "Agreement"), pursuant to which ESI provides certain prescription drug benefit management services to Sponsor.
- B. Sponsor and ESI desire to update and amend the Agreement in accordance with the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the premises and other conditions contained herein, the parties hereto hereby agree as follows:

TERMS OF AMENDMENT

- 1. <u>Definitions</u>. For purposes of this Amendment, any capitalized term not otherwise defined herein shall have the meaning set forth in the Agreement.
- Coverage of COVID-19 Oral Antiviral Therapeutic Products. Sponsor wishes to provide coverage for SARS-CoV2 oral antiviral therapeutic products (currently Paxlovid and Molnupiravir) authorized by the Food and Drug
 Administration's emergency use authorization, as amended (the "COVID-19 Oral Antiviral Products") under its
 pharmacy benefit. ESI shall maintain the list of covered COVID-19 Oral Antiviral Products and shall make such
 list available to Sponsor upon request.
- 3. <u>Exclusion of COVID-19 Oral Antiviral Products from Guarantees</u>. Sponsor agrees that notwithstanding anything in the PBM Agreement to the contrary, claims for such COVID-19 Oral Antiviral Products shall be excluded from all financial and rebate guarantees under the Agreement.
- 4. <u>Claims Reimbursement and Fees</u>. Client will pay to ESI the following amounts for COVID-19 Oral Antiviral Products:

	Participating Pharmacy COVID-19 Oral Antiviral Products
Ingredient Cost	\$0*
Dispensing Fee	Pass-Through up to \$12.00**
COVID-19 Oral Antiviral Products Program	\$2.50 per claim for COVID-19 Oral Antiviral Product
Fee	

The \$0 ingredient cost shall apply for approved medications while funded by the federal government. If COVID-19 Oral Antiviral Products are no longer funded by the federal government, the ingredient cost shall be the Participating Pharmacy Ingredient Cost as set forth in the Agreement.

- 5. Effective Date. This Amendment shall be effective January 14, 2022.
- 6. <u>Effect of Amendment</u>. Except as expressly provided herein, the terms and conditions of the Agreement shall remain in full force and effect. In the event of a conflict between this Amendment and the Agreement, the terms of this Amendment shall prevail.

[&]quot;The Pass-Through arrangement shall apply for approved medications while funded by the federal government. If the Dispensing Fee increases to exceed \$12.00, both parties acknowledge that an additional amendment is necessary. If COVID-19 Oral Antiviral Products are no longer funded by the federal government, the Dispensing Fee shall be the Participating Pharmacy Dispensing Fee as set forth in the Agreement.

IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the day and year below set forth.

EXPRESS SCRIPTS, INC.	COUNTY OF VENTURA as owner and operator of the VENTURA COUNTY HEALTH CARE PLAN
Ву:	
	Ву:
Printed Name:	,
	Printed Name:
Title:	-
Data	Title:
Date:	Date:
Date:	Date: